WS6inducer of β cell proliferation CAS# 1421227-53-3 |
- TPCA-1
Catalog No.:BCC2473
CAS No.:507475-17-4
- Sodium salicylate
Catalog No.:BCC4846
CAS No.:54-21-7
- Sodium 4-Aminosalicylate
Catalog No.:BCC4609
CAS No.:6018-19-5
- IKK-16 (IKK Inhibitor VII)
Catalog No.:BCC4555
CAS No.:873225-46-8
- IMD 0354
Catalog No.:BCC4556
CAS No.:978-62-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1421227-53-3 | SDF | Download SDF |
| PubChem ID | 71566751 | Appearance | Powder |
| Formula | C29H31F3N6O3 | M.Wt | 568.59 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (175.87 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-[6-[4-[2-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)anilino]-2-oxoethyl]phenoxy]pyrimidin-4-yl]cyclopropanecarboxamide | ||
| SMILES | CN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)CC3=CC=C(C=C3)OC4=NC=NC(=C4)NC(=O)C5CC5)C(F)(F)F | ||
| Standard InChIKey | FTODTDQFHDJWIQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C29H31F3N6O3/c1-37-10-12-38(13-11-37)17-21-6-7-22(15-24(21)29(30,31)32)35-26(39)14-19-2-8-23(9-3-19)41-27-16-25(33-18-34-27)36-28(40)20-4-5-20/h2-3,6-9,15-16,18,20H,4-5,10-14,17H2,1H3,(H,35,39)(H,33,34,36,40) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | WS6 is a novel small molecule that promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability).
EC50 value: 0.28 uM [1]
Target: β cell proliferation agonist
in vitro: WS6 induced up to 4% of rat β cells to proliferate, with an EC50 of 0.4 μM. In the same format, WS6 also induced 3% of human β cells to proliferate, with a similar potency to the rat β cells. WS6 induced R7T1 proliferation in dose response, with EC50 value of 0.28 μM, Proliferation of R7T1 cells, which are cultured in suspension and grow as clusters, was apparent by visible inspection.
in vivo: RIP-DTA mice were fed Dox in the drinking water until the onset of overt diabetes (blood glucose reading >300 mg/dL, typically 4-10 days), at which point Dox treatment was discontinued and treatment with WS6 was initiated (5 mg/kg every other day via intraperitoneal injection). Pharmacokinetic studies with WS6 at 50 mg/kg revealed a CMAX of ～5 μM and T1/2 of ～2 h. Treatment with WS6 caused a progressive reduction of blood glucose over time, starting around 2 weeks. References: | |||||
WS6 Dilution Calculator
WS6 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7587 mL | 8.7937 mL | 17.5874 mL | 35.1747 mL | 43.9684 mL |
| 5 mM | 0.3517 mL | 1.7587 mL | 3.5175 mL | 7.0349 mL | 8.7937 mL |
| 10 mM | 0.1759 mL | 0.8794 mL | 1.7587 mL | 3.5175 mL | 4.3968 mL |
| 50 mM | 0.0352 mL | 0.1759 mL | 0.3517 mL | 0.7035 mL | 0.8794 mL |
| 100 mM | 0.0176 mL | 0.0879 mL | 0.1759 mL | 0.3517 mL | 0.4397 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
WS6 is a small-molecule inducer of β cell proliferation [1].
β cells are a subset of cells in the pancreatic islets and play an important role in regulating glucose homeostasis through the production of insulin [1].
WS6 is a small-molecule inducer of β cell proliferation. In mouse β cell line R7T1, WS6 induced cell proliferation with EC50 value of 0.28 µM. WS6 was very active in primary human and rodent islets. In primary rat and human β cells, WS6 induced rat β cell proliferation with EC50 value of 0.4 µM and increased 4% of rat β cells and 3% of human β cells to proliferate. In intact islet cultures, WS6 significantly induced proliferation [1]. In cultured human islets, WS6 induced β cell proliferation and also α cell proliferation. However, WS6 didn’t influence the expression of β cell-specific transcription factors and the amount of insulin-positive β cells, which suggested that WS6 didn’t influence β cell differentiation and human islet cell viability [2].
In type 1 diabetes (T1D) mice, WS6 significantly reduced blood glucose and increased β cell proliferation from 3.8% to 6.4% [1].
References:
[1]. Shen W, Tremblay MS, Deshmukh VA, et al. Small-Molecule Inducer of β Cell Proliferation Identified by High-Throughput Screening. J Am Chem Soc, 2013, 135(5): 1669-1672.
[2]. Boerner BP, George NM, Mir SU, et al. WS6 induces both alpha and beta cell proliferation without affecting differentiation or viability. Endocr J, 2015, 62(4): 379-386.
- WS 3
Catalog No.:BCC7519
CAS No.:1421227-52-2
- Isosalvianolic acid C
Catalog No.:BCN3476
CAS No.:142115-17-1
- BIM 189
Catalog No.:BCC5934
CAS No.:142062-55-3
- Caproic acid
Catalog No.:BCC9218
CAS No.:142-62-1
- NVP-TNKS656
Catalog No.:BCC6541
CAS No.:1419949-20-4
- NSC 625987
Catalog No.:BCC7269
CAS No.:141992-47-4
- Methyl 4-Hydroxyphenylacetate
Catalog No.:BCN1571
CAS No.:14199-15-6
- Emetine Hydrochloride
Catalog No.:BCN2478
CAS No.:14198-59-5
- 16-Hydroxycleroda-3,13-dien-15,16-olide
Catalog No.:BCN7500
CAS No.:141979-19-3
- 14-Deoxy-11,12-didehydroandrographiside
Catalog No.:BCN1572
CAS No.:141973-41-3
- Ginsenoside Rg3
Catalog No.:BCN1068
CAS No.:14197-60-5
- Ginsenoyne K
Catalog No.:BCN3953
CAS No.:141947-42-4
- (+)-Ketoconazole
Catalog No.:BCC4249
CAS No.:142128-59-4
- CYM 50769
Catalog No.:BCC6337
CAS No.:1421365-63-0
- Mutated EGFR-IN-1
Catalog No.:BCC5444
CAS No.:1421372-66-8
- Mutant EGFR inhibitor
Catalog No.:BCC4119
CAS No.:1421373-62-7
- AZD-9291
Catalog No.:BCC4120
CAS No.:1421373-65-0
- AZD-9291 mesylate
Catalog No.:BCC4121
CAS No.:1421373-66-1
- AZ5104
Catalog No.:BCC6389
CAS No.:1421373-98-9
- LY3039478
Catalog No.:BCC2105
CAS No.:1421438-81-4
- Sweroside
Catalog No.:BCN6219
CAS No.:14215-86-2
- Hederacoside C
Catalog No.:BCN2329
CAS No.:14216-03-6
- GZD824
Catalog No.:BCC4389
CAS No.:1421783-64-3
- KPT-276
Catalog No.:BCC4445
CAS No.:1421919-75-6
WS6 induces both alpha and beta cell proliferation without affecting differentiation or viability.[Pubmed:25739404]
Endocr J. 2015;62(4):379-86.
Agents that stimulate human pancreatic beta cell proliferation are needed to improve diabetes mellitus treatment. Recently, a small molecule, WS6, was observed to stimulate human beta cell proliferation. However, little is known about its other effects on human islets. To better understand the role of WS6 as a possible beta cell regenerative therapy, we carried out in-depth phenotypic analysis of WS6-treated human islets, exploring its effects on non-beta cell proliferation, beta cell differentiation, and islet cell viability. WS6 not only stimulated beta cell proliferation in cultured human islets (in agreement with previous reports), but also human alpha cell proliferation, indicating that WS6 is not a beta cell-specific mitogen. WS6 did not change the proportion of insulin-positive beta cells or the expression of beta cell-specific transcription factors, suggesting that WS6 does not alter beta cell differentiation, and WS6 had no effect on human islet cell apoptosis or viability. In conclusion, WS6 stimulates proliferation of both human beta and alpha cells while maintaining cellular viability and the beta cell differentiated phenotype. These findings expand the literature on WS6 and support the suggestion that WS6 may help increase human islet mass needed for successful treatment of diabetes.
